Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (Nasdaq: NKTR) announced a research collaboration with UCSF and Dr. Stephen L. Hauser to study NKTR-0165, a first-in-class TNFR2 agonist antibody, in multiple sclerosis models. UCSF will conduct and fund the research; Nektar will supply NKTR-0165 and retain program rights.
The work will test TNFR2 agonism for neuroprotection, reduced neurodegeneration, and cell repair in neuron exposures to patient-derived B cells.
Nektar Therapeutics (Nasdaq: NKTR) closed an underwritten public offering that generated approximately $460 million in gross proceeds on Feb 13, 2026. The company sold 7,637,931 shares (including 1,034,482 shares from full exercise of the underwriters' option) and 293,103 pre-funded warrants.
Shares were priced at $58.00 per share and pre-funded warrants at $57.9999, before underwriting discounts, commissions and offering expenses. Jefferies, TD Cowen and Piper Sandler led the deal.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized public offering to raise approximately $400 million by selling 6,603,449 common shares and 293,103 pre-funded warrants at $58.00 (or $57.9999 for warrants) per unit.
The offering may close on February 13, 2026, includes a 30-day underwriter option for up to 1,034,482 additional shares, and intends net proceeds for general corporate purposes, including Phase 3 rezpegaldesleukin development and manufacturing.
Nektar Therapeutics (Nasdaq: NKTR) on Feb. 10, 2026 announced a proposed underwritten public offering of $300,000,000 of common stock and, for certain investors, pre-funded warrants, with a 30-day option for up to an additional $45,000,000. The offering is subject to market conditions.
Proceeds are intended for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin), and manufacturing. Jefferies, TD Cowen, and Piper Sandler are joint bookrunning managers. The securities will be offered under a Form S-3ASR shelf registration that became effective Nov. 12, 2025.
Nektar Therapeutics (Nasdaq: NKTR) reported 36-week blinded maintenance results from the 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Key findings: durable EASI-75/EASI-90 and vIGA-AD 0/1 maintenance with 24 µg/kg Q4W and Q12W, up to 5-fold increases in EASI-100 during maintenance, favorable safety with 3.5% discontinuation for adverse events, and plan to advance to Phase 3 with a target BLA submission in 2029.
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on February 10, 2026 at 8:00 am ET to review topline results from the 36‑week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
According to the company, a morning press release will publish the results, slides will be posted on the Nektar investor events page, and a replay will be available for at least 30 days.
Nektar Therapeutics (NASDAQ: NKTR) announced that on January 21, 2026 its Organization and Compensation Committee granted non-qualified stock options to purchase 1,600 shares to one newly hired employee under the 2025 Inducement Plan.
The options have an exercise price of $36.92 (closing price on January 21, 2026), an eight-year term, and vest over four years (25% after one year, then monthly 1/48ths).
Nektar Therapeutics (Nasdaq: NKTR) reported topline 36-week results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin in 92 patients with severe-to-very-severe alopecia areata. Both dose arms showed mean SALT score reductions of 28.2% (24 µg/kg) and 30.3% (18 µg/kg) versus 11.2% for placebo; the primary endpoint narrowly missed statistical significance in the mITT population. Excluding four patients with major eligibility violations, the primary endpoint reached significance (29.6% and 30.4% vs 5.7%, p=0.049 and p=0.042). Key secondary outcomes (SALT30, SALT≤30/20/10) favored treatment. Safety was described as well tolerated with mostly mild-to-moderate TEAEs and a 1.4% discontinuation rate in treatment arms. Nektar plans to advance rezpegaldesleukin to Phase 3 in 2026 and will present additional data in 2026.
Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.
The event is scheduled for December 16, 2025 at 8:00 AM ET / 5:00 AM PT. Results will be released in a morning press release and presented on the webcast; slides and the press release will be posted in the company's events section at https://ir.nektar.com/events-and-presentations/events. A replay will be available for at least 30 days after the event.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for two newly hired employees totaling 18,310 non-qualified stock options under Nektar's 2025 Inducement Plan.
Grant details: 7,260 options granted on Nov 25, 2025 at an exercise price of $60.35 (closing price that day), and 11,050 options granted on Dec 4, 2025 at an exercise price of $57.69 (closing price that day). Options have an 8-year term and vest over 4 years with 1/4 vesting after one year and the remainder vesting monthly over the next three years, subject to continued employment and plan/option agreement terms.